Test could help determine which patients respond to immunotherapies.
Regulator is exploring safety of immunotherapy combinations in blood cancer
Boehringer to progress R&D partnership that began last year
PARADIGM study meets primary endpoint.
Regulator reviewing combination therapy safety after issue with Keytruda
Trading in shares of Daiichi Sankyo was suspended yesterday.